Hepadnaviridae infectious disease

This early-stage study tested a new experimental drug called GSK3965193, alone and in combination with another drug (bepirovirsen), for people with chronic hepatitis B. The goal was to see if the combination could lower hepatitis B virus levels and possibly lead to a sustained re…

This study tested two antiviral drugs, clevudine and tenofovir, alone or together, in 150 adults with chronic hepatitis B who had not been treated before. The goal was to see which approach worked best at controlling the virus after 96 weeks of treatment and 24 weeks of follow-up…

This study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow…

This early-stage study tested a new medicine called RO7565020 in healthy volunteers and people with chronic hepatitis B. The goal was to see if the drug is safe and how the body processes it. The trial was stopped early, so results are limited.

This Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated …

This study tested a new drug called ARC-520 in 79 people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it combined with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen l…

This early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited.

This study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. …

This study tested whether a new drug called ARC-520, given with the standard medicine entecavir, could lower hepatitis B virus levels in people with chronic hepatitis B. About 58 adults with different stages of infection received either ARC-520 or a placebo. The study was stopped…

This study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking antiviral medications (entecavir or tenofovir). The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial wa…

This study tested a treatment called HepTcell, which is like a vaccine that trains the immune system to fight the hepatitis B virus. It was for people with inactive chronic hepatitis B who had not received treatment before. The goal was to see if it could lower virus levels or cl…

This study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels. Only 4 people enrolled before the study was stop…

This small phase 2 trial tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen in people with chronic hepatitis B. Only 13 patients were enrolled before the study was terminated. The goal was to see if a 12-week course of injections could…

This study looked at how the hepatitis B vaccine triggers immune cells called B cells to form germinal centers, where antibodies become stronger. Researchers wanted to understand if memory B cells return to these centers after a booster shot. The goal was to learn how to design b…

This study tested whether placing a reminder sticker on the charts of adult hospital patients receiving IV fluoroquinolone antibiotics would encourage doctors to switch them to oral pills sooner. The trial involved 168 patients at a single hospital in Thailand. Unfortunately, the…

This study observed over 1,700 adults with chronic hepatitis B in the US and Canada to understand how the disease progresses and how treatments are used in everyday medical practice. Researchers collected data from both academic and community clinics to build a real-world picture…